Asset Details
Do you wish to reserve the book?
Safety, tolerability and immunogenicity of a quadrivalent recombinant norovirus vaccine (Pichia pastoris) in participants six weeks of age or older: Phase I/IIa trial
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Safety, tolerability and immunogenicity of a quadrivalent recombinant norovirus vaccine (Pichia pastoris) in participants six weeks of age or older: Phase I/IIa trial
Do you wish to request the book?
Safety, tolerability and immunogenicity of a quadrivalent recombinant norovirus vaccine (Pichia pastoris) in participants six weeks of age or older: Phase I/IIa trial
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Safety, tolerability and immunogenicity of a quadrivalent recombinant norovirus vaccine (Pichia pastoris) in participants six weeks of age or older: Phase I/IIa trial
2025
Overview
Noroviruses are the leading cause of epidemic acute gastroenteritis and foodborne diarrheal disease in humans. Here, a randomized, double-blind, multi-cohort, placebo-controlled clinical trial was performed to determine the candidate vaccine's safety and immunogenicity. The experimental framework incorporated an initial Phase I age/dose-escalation stage followed by a Phase IIa dose-expansion component. A total of 580 participants (five groups: 6 weeks to 23 months, 2-5 years, 6-17 years, 18-59 years, and ≥60 years) were randomized into 13 groups to receive intramuscular injections of either a placebo (aluminium-containing or aluminium-free) or vaccine formulation (low-dose or high-dose) on days 0, 30 and 60. The safety outcomes included the incidence of all adverse events within 0-30 days post-vaccination and all serious adverse events within 6 months. Immunogenicity analyses focused on seroconversion rates against four norovirus genotypes (GI.1, GII.3, GII.4, GII.17) at 30 days post-third vaccination, including IgA, IgG and histoblood group antigen (HBGA)-blocking antibodies (BT50). The results of the Phase I and Phase IIa clinical trials indicated that the IgA seroconversion rates against the four norovirus genotypes at 30 days post-third vaccination were 49.45-86.81% in the low-dose group versus 66.12-85.25% in the high-dose group. IgG seroconversion ranged from 63.74% to 93.41% (low-dose) and 72.13% to 92.35% (high-dose), while HBGA-blocking antibody responses ranged from 64.84-86.26% (low-dose) and 78.14-89.62% (high-dose). Adverse reactions predominantly occurred within 0-7 days post-vaccination, with Grade 1-2 events predominating. The most frequent reactions included injection-site pain and fever. This trial is registered at www.chictr.org.cn (ChiCTR2400089762).
Publisher
Taylor & Francis Ltd,Taylor & Francis,Taylor & Francis Group
Subject
/ Adult
/ Aged
/ Antibodies, Viral - immunology
/ Caliciviridae Infections - immunology
/ Caliciviridae Infections - prevention & control
/ Caliciviridae Infections - virology
/ Child
/ Female
/ Gastroenteritis - immunology
/ Gastroenteritis - prevention & control
/ Humans
/ Infant
/ Male
/ vaccine
/ Vaccines
/ Vaccines, Synthetic - administration & dosage
/ Vaccines, Synthetic - adverse effects
/ Vaccines, Synthetic - immunology
/ Viral Vaccines - administration & dosage
